TORREY PINES
INVESTMENT

Home About Us News Portfolio Contacts

Viriom Obtains First Market Approval of Elsulfavirine (Elpida®) for Treatment of HIV-1 Infection in Russia

NewVac Presented Results of Quisinostat’s Phase II Clinical Trial at ASCO 2017

Viriom to Present Results of Pre-Clinical Pharmacokinetic Studies with Elsulfavirine and VM1500A Long Acting Injectable Formulations at the International AIDS Society (IAS) Conference 2017

TealTech Capital Invests in the Mobile Medical Office Technology Platform for Rapid On-Site Healthcare Services Based on Point-of-Care Diagnostics and Telemedicine

Torrey Pines Investment Establishes a $60 Million TealTech Fund to Support Point-of-Care Medicine

Avelas Biosciences Appoints Steven Chen as Chief Medical Officer

Leap Therapeutics to Present DKN-01 Clinical Data at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

Torrey Pines Investment Attends Inauguration of the German Center for Neurodegenerative Diseases (DZNE) in Bonn, Germany

Avelas Biosciences Appoints Alexey Vinogradov, Ph.D., to Board of Directors

Avelas Biosciences to Present at 29th Annual Roth Conference

Leap Therapeutics to Present at 2017 Barclays Global Healthcare Conference

Leap Therapeutics to Present Preclinical and Clinical Data at 2017 AACR Annual Meeting

Viriom Reports Positive Findings in 48 Week Study of Elsulfavirine as Compared to Efavirenz in Combination with TDF/FTC at CROI 2017

ChemDiv Announces Multi-Year Hit Identification Collaboration with Janssen

Viriom to Present Positive Clinical Findings for Elsulfavirine vs Efavirenz in Combination with TDF/FTC

ChemDiv Announces Key Milestones in Abbott Pharma Collaboration

Viriom Announces Collaboration with NIH on Zika and Other Major Viral Diseases

NewVac Reports Primary Endpoint Met in Phase II Clinical Trial of Quisinostat in Combination with Paclitaxel and Carboplatin in Platinum-Resistant Ovarian Cancer

Viriom Announces Appointment of New Scientific Advisory Board Member

ChemDiv, Torrey Pines Investment and DZNE Announce Research Collaboration

Leap Therapeutics and Macrocure Announce Definitive Merger Agreement

Avelas Biosciences Completes $20 Million Series C Financing

SatRx LLC Announces First Registration in Russia of SatRx® (gosogliptin), an Innovative Drug for Treatment of Type 2 Diabetes

BioIntegrator, LLC Announces the Second Market Registration of Nescler®, a First Generic of the Novartis MS Blockbuster Gilenya®

Viriom Announces Receipt of Funding from the Skolkovo Foundation, ChemRar and Torrey Pines Investment to Develop Elsulfavirine, a Novel Preventive and Long-acting Treatment of HIV/AIDS

Avelas Biosciences Announces Positive Interim Phase 1b Results and Advances to Dose Expansion Stage

The President of Tatarstan discussed cooperation with Torrey Pines Investment in the field of pharmaceuticals and novel agricultural products

Chromis Successfully Secures Seed Funding from Torrey Pines Investment

ChemDiv and Abbott expand collaboration to develop branded generic pharmaceuticals for high growth emerging markets

Tensha Therapeutics To Be Acquired By Roche

ChemDiv Announces Achievement of a Development Milestone in a Drug Discovery Collaboration With Janssen

BioIntegrator Announced Launch of Nescler® -- a Generic of Novartis MS Blockbuster Gilenya® in Emerging Markets

J.P. Morgan 34th Annual Healthcare Conference

Viriom presented the results of the safety and antiviral effect of its novel drug Elsulfavirine at the EACS-2015 conference in Barcelona

Avineuro LLC  advances its highly selective 5-HT6R antagonist program in Alzheimer Disease

TeaRx launches an innovative anticoagulant Tearexaban

Ron Demuth Interviewed for Nature Drug Discovery News Article

Avelas Biosciences Completes 7.4M Funding

T23 Announces Global License of SCRIPPS’ CD22 Siglec Oncoimmunological Platform for B-cell Tumors

Viriom is Expanding its Portfolio of Novel Antiviral Drugs

ChemRar HighTech Center is featured in Pharmaceutical Executive article “Russia’s Bet on Biopharma”

 

 

Our Team
Ronald M.B.S. Demuth, President
Tel: 858.724.0581 E-mail: rdemuth@torreypinesinv.com
 

Mr. Demuth is the founding President of Torrey Pines Investment, responsible for the company’s strategic investments.

Prior to his work at Torrey Pines, he worked as a business consultant to biotech startups, as General Manager of Integrated Genomics, and in several roles at The University of Chicago, including work as an Administrator and as a technology advisor to the Arch Venture corporation.

Mr. Demuth has 30 years of research and management experience in the international life science industry and academia.

 

   
Nikolay Savchuk, Ph.D.,Managing Director
Tel: 858.794.4860 ext. 310 E-mail: nsavchuk@torreypinesinv.com
 

Nikolay Savchuk, Ph.D., is a serial entrepreneur and an experienced international investor in the healthcare and IT industries for 23 years. Dr. Savchuk is the executive Chairman of Chromis Therapeutics; Viriom, Inc.; Member of the Board of Directors at Avelas (San Diego, CA); CEO of ChemDiv; Member of the Board of ChemRar High Tech Center, and co-founder of ChemRar Ventures (Moscow, Russia); Chairman of the Board of Directors of its companies: Chemical Diversity Research Institute, NewVac, TeaRx, and SatRx. He is also co-chair of the Joint Investment Committees between ChemRar Ventures and JJDC (New Brunswick, NJ), Torrey Pines Investment and BioMotiv (Cleveland, OH).

Dr. Savchuk is a member of the U.S.-Russian Bilateral Presidential Commission’s Working Group on Health, a member of the expert council of the Agency of Strategic Initiatives and New Projects of the Russian government, a member of the Board of the non-profit BioPharmClutster Northern, co-founder and member of the Advisory Board Initiative "PhysTech 21" and the Director for Strategic Development of the Moscow Institute of Physics and Technology (MIPT). Dr. Savchuk was a co-founder of the Inel Group of IT and media companies in Singapore and Russia, and he managed several of its companies.

The scope of Dr. Savchuk’s main interest is the life sciences, including rational drug design, drug development and digital health technologies. Dr. Savchuk leads and continues to manage successful investments in pharmaceutical and drug development companies.

Dr. Savchuk obtained an MS degree in physics in 1994 and a Ph.D. in applied mathematics in 2000 from the Moscow Institute of Physics and Technology. He is an inventor and author of over 100 patents and research publications.

   
Michael G. Palfreyman, Ph.D., DSc, R&D Diligence
Tel: 617-314-6439 Cell: 978-884-4861 E-mail: mpalfreyman@torreypinesinv.com
 

Michael Michael G. Palfreyman is a seasoned leader in the biotechnology and pharmaceutical industries with over 35 years of experience. He has been an invited speaker and chairperson for a number of international and national conferences, is a co-inventor on 35 issued US patents and three pending patents, and a co-author of over 150 scientific articles and book chapters. Dr. Palfreyman is currently Head, Translational R&D at ChemDiv, Inc. as well as Senior Scientific Advisor for Vitruvean, Inc.

Previously, Michael was Vice President, Program Management & Product Development at EnVivo Pharmaceuticals where he was responsible for the late-stage discovery and preclinical development of two CNS drugs now demonstrating efficacy in clinical testing. As a co-founder of NOVACE Corporation, Michael worked closely with investors and biotechnology companies to bring products from discovery through to the value point of clinical validation.

Before joining NOVACE, Michael held a number of executive positions at Psychiatric Genomics and Scriptgen (Anadys) Pharmaceuticals, as well as Marion Merrell Dow Research Institute (Sanofi-Aventis). In addition to overseeing research programs in Psychiatric, Neurological, Cardiovascular, Cancer, Infectious, Metabolic and Respiratory Disorders, Dr. Palfreyman’s own research included discovery and development of a number of psychotherapeutic compounds for treatment of psychosis, depression, stroke, epilepsy, emesis, Parkinsons, and Alzheimers diseases. Many of these compounds have entered clinical development and a number have reached the marketplace.

   
Ian Wisenberg, M.B.A., Venture Adviser
Tel: 858 722-2552 E-mail: iwisenberg@torreypinesinv.com
 

Ian Wisenberg has more than 25 years experience in international business with an emphasis in finance, capital formation, business development and administration. He is founder and managing partner of BioGlobal Consulting Group (BGCG). Prior to founding BioGlobal Consulting Group, he served as the Senior Vice President of Business Development and CFO of BIOCOM – the world’s largest regional life science trade organization.

Bringing a broad portfolio of expertise, Ian has a solid track record in capital development initiatives aimed at establishing strategic financial partnerships with local, national and international financing institutions. He was also responsible for establishing the VC incubator in San Diego. Of equal significance is his ability to foster international relations with government agencies and private institutions.

Mr. Wisenberg also serves on the Board of Directors for two San Diego biotech companies and is treasurer for the San Diego Venture Group. Prior to BIOCOM, he was Vice President of Finance and Administration, as well as Interim President, Secretary and Treasurer of Aerocast, Inc., a secured broadband media streaming company. Mr. Wisenberg holds a Bachelor of Commerce Degree in accounting from Cape Town University and is a Certified Public Accountant.

   
Gelena Lifchitz, MD, MPH, Business Development Director
Cell: 858-363-4108 E-mail: glifschitz@torreypinesinv.com
 

Gelena is an experienced project manager with deep knowledge of life science technologies and international healthcare and biotech markets. Prior to joining Torrey Pines Investment, Gelena led the BioMed Cluster of the Skolkovo Foundation – the largest biotech incubator in modern Russia. She managed over 85 biotech start-ups and was awarded "the best employee award" twice.

Earlier, Gelena was a marketing director at a leading drug distributor, where she launched over 20 new products bringing revenues of $200 million to the company. Gelena received her MD degree at Ural State Medical Academy and won the International Muskie Fellowship to study and receive an MPH Management degree from UCLA, USA.

   
Nicholas A. Saccomano, Ph.D.,Venture Adviser
Tel: 303-625-9036 Cell: 541-550-0614 E-mail: nsaccomano@torreypinesinv.com
 

Nick Saccomano has worked in the pharmaceutical and biotech industries for the past 25 years. During that time he has managed drug discovery and development programs, as well as the multi-disciplinary core technology departments that support the R&D process. Nick began his career at Pfizer in 1984 in CNS drug discovery. During his time in this group, he had the good fortune to be part of teams that brought important new compounds to and through development in areas of great medical need such as depression, anxiety, psychosis and Alzheimer’s disease. In 1998 Nick was promoted to Vice President in charge of discovery technology, developing and managing a broad array of scientific disciplines including computational sciences, genomics, proteomics and high-throughput chemistry and biology.

In 2004 Nick was promoted to Senior Vice President at Pfizer in charge of Strategic Alliances/Business Development. In 2008 Nick joined Bend Research, a drug formulation and delivery company, as CSO and in 2010 he moved to SomaLogic, a proteomic-based diagnostic discovery and development organization as CTO. He remains an active advisor and/or Board member for many organizations and institutions including Bend Research, Sea Lane Biotechnologies, ChemDiv, Colorado Bioscience Association and Northwestern University.

Nick graduated from the State University of New York at Buffalo in 1980 with a B.S. in chemistry and subsequently from Columbia University in 1984 with a Ph.D. in synthetic organic chemistry under the guidance of Professor Gilbert Stork.

TORREY PINES
INVESTMENT

6605 Nancy Ridge Drive, Ste 207, San Diego CA 92121
T: (858) 724-0581   F: (858) 345-3761
Home About Us News Portfolio Contacts